A long-acting interleukin-7, rhIL-7-hyFc, enhances CAR T cell expansion, persistence, and anti-tumor activity

Chimeric antigen receptor (CAR) T cell therapy is routinely used to treat patients with refractory hematologic malignancies. However, a significant proportion of patients experience suboptimal CAR T cell cytotoxicity and persistence that can permit tumor cell escape and disease relapse. Here we show...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Miriam Y., Jayasinghe, Reyka, Devenport, Jessica M., Ritchey, Julie K., Rettig, Michael P., O’Neal, Julie, Staser, Karl W., Kennerly, Krista M., Carter, Alun J., Gao, Feng, Lee, Byung Ha, Cooper, Matthew L., DiPersio, John F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9192727/
https://www.ncbi.nlm.nih.gov/pubmed/35697686
http://dx.doi.org/10.1038/s41467-022-30860-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9192727/
https://www.ncbi.nlm.nih.gov/pubmed/35697686
http://dx.doi.org/10.1038/s41467-022-30860-0

Ejemplares similares